Cited by 998Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record; 390 of the 393 references it cites were found in a registry or an index.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S, Duncan, G E, Marx, C E, Lieberman, J A·2005·Molecular Psychiatry

DOI 10.1038/sj.mp.4001556

Open this paper in CoChat — free account

Abstract

The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development. Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems. Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia. However, the pharmacological properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life. Moreover, the efficacy of antipsychotic drugs is limited prompting the clinical use of adjunctive pharmacy to augment the effects of treatment. In addition, the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiologic hypotheses. This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001556

Cites

390 of 390 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glutamate uptake
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D. A., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,416
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
Tol, H. H. M. V., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P. M., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,015
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793

Show all 393 references

Research works printed but not linked: 15

Breier A, Wright P, Birkett M, Meehan K, David, Brook S . A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients, ACNP 39th Annual Meeting Abstract. American College of Neuropsychopharmacology: Puerto Rico, 2000.
Waddington J, Casey D . Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Buckley PF, Waddington JL (eds). Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann: Woburn, MA, 2000, pp 3–13.
Carlsson A . Focusing on dopaminergic stabilizers and 5-HT2A receptor antagonists. Curr Opin CPNS Invest Drugs 2000; 2: 22–24.
Patel JK, Pinals DA, Breier A . Schizophrenia and other psychoses. In: Tasman A, Kay J, Lieberman JA (eds). PSYCHIATRY, 2nd edn. John Wiley & Sons, Ltd: Chichester, 2003, pp 1131–1206.
Ferris P . Ziprasidone. Curr Opin CPNS Invest Drugs 2000; 2: 58–70.
Nichols DE, Mailman RB . Substituted hexa-hydro[a]phenanthridines. US Patent 1995; 5: 134.
Nichols DE, Mailman RB . Fused isoquinolines as dopamine receptor ligands. US Patent 1999; 5: 110.
Danysz W . Sonepiprazole. Curr Opin CPNS Invest Drugs 2000; 2: 97–104.
Mansbach RS, Brooks EW, Sanner MA, Zorn SH . Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 1998; 135: 194–200. · DOI
Abi-Saab WM, D'Souza DC, Madonick SH, Krystal JH . Targeting the glutamate system. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 304–332.
Goff D, Berman I, Posever T, Leahy L, Lynch G . A preliminary dose-escalation trial of CX 516 (ampakine) added to clozapine in schizophrenia. Schizophr Res 1999; 36: 280.
Bymaster FP . Possible role of muscarinic receptor agonists as therapeutic agents for psychosis. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 333–348.
Perry KW, Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Zhang W et al. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr Res 1999; 36: 117–118.
Basile VS, Masellis M, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL . Application of pharmacogenetics to schizophrenia: Emerging insights from studies of clozapine response and tardive dyskinesia. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 85–110.
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) Project: Schizophrenia trial design and protocol development. Schizophrenia Bull 2003; 29: 15–31. · DOI

Sorted by citations

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citation
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803
Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial
McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 584
Self-citation
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C. H., Bymaster, F. P., McKinzie, D. L., & Felder, C. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.06091591 · Cited by 563
Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies
Fusar-Poli, P., Smieskova, R., Kempton, M. J., Ho, B. C., Andreasen, N. C., & Borgwardt, S. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.06.001 · Cited by 512
Transient and Selective Overexpression of Dopamine D2 Receptors in the Striatum Causes Persistent Abnormalities in Prefrontal Cortex Functioning
Kellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 405
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors
Bateup, H. S., Santini, E., Shen, W., Birnbaum, S. G., Valjent, E., Surmeier, D., Fisone, G., Nestler, E. J., & Greengard, P. (2010) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1009874107 · Cited by 361
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de León, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 355
Atypical Antipsychotic Agents in the Treatment of Violent Patients With Schizophrenia and Schizoaffective Disorder
KRAKOWSKI, M. I., Czobor, P., Citrome, L., Bark, N. M., & Cooper, T. B. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.622 · Cited by 350
Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia
Demjaha, A., Murray, R. M., McGuire, P. K., Kapur, S., & Howes, O. D. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010144 · Cited by 355
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 342
Psychosis pathways converge via D2High dopamine receptors
Seeman, P. M., Schwarz, J., Chen, J., Szechtman, H., Perreault, M. L., McKnight, G. S., Roder, J., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 333
Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics
Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803522105 · Cited by 320
Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Mailman, R., & Murthy, V. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361461 · Cited by 311
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Koblan, K. S., KENT, J. M., Hopkins, S. C., Krystal, J. H., Cheng, H., GOLDMAN, R. S., & Loebel, A. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911772 · Cited by 311
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Peng, J., Fan, M., An, C., Ni, F., Huang, W., & Luo, J. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13710 · Cited by 315
HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity
Kurita, M., Holloway, T. D., García‐Bea, A., Kozlenkov, A., Friedman, A. K., Moreno, J. L., Heshmati, M., Golden, S. A., Kennedy, P., Takahashi, N., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3181 · Cited by 282
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 261
Clinical pharmacology of atypical antipsychotics: an update
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014) · Technische Universität Dortmund · doi:10.17877/de290r-7037 · Cited by 250
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
Meltzer, H. Y., & HUANG, M. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00909-6 · Cited by 248
Cell type–specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs
Bateup, H. S., Svenningsson, P., Kuroiwa, M., Gong, S., Nishi, A., Heintz, N., & Greengard, P. (2008) · Nature Neuroscience · doi:10.1038/nn.2153 · Cited by 233
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm074 · Cited by 227
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 225
Self-citation
Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials
Kishi, T., Matsuda, Y., Nakamura, H., & Iwata, N. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.10.011 · Cited by 221
Transient Overexpression of Striatal D2 Receptors Impairs Operant Motivation and Interval Timing
Drew, M. R., Simpson, E., Kellendonk, C., Herzberg, W., Lipatova, O., Fairhurst, S. P., Kandel, E., Malapani, C., & Balsam, P. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1736-07.2007 · Cited by 220
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Self-citation
Zebrafish models in neuropsychopharmacology and CNS drug discovery
Khan, K. M., Collier, A. D., Мешалкина, Д. А., Kysil, E. V., Khatsko, S. L., Kolesnikova, T. O., Morzherin, Y. Y., Warnick, J. E., Kalueff, A. V., & Echevarria, D. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13754 · Cited by 217
Ionotropic Glutamate Receptors & CNS Disorders
Bowie, D. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708784083821 · Cited by 207
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 204
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction
Zhang, J., & Malhotra, A. K. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.532787 · Cited by 194
Dissociation between In Vivo Occupancy and Functional Antagonism of Dopamine D2 Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models
Natesan, S., Reckless, G. E., Nóbrega, J. N., Fletcher, P. J., & Kapur, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300983 · Cited by 193
Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia
Wonodi, I., & Schwarcz, R. M. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq002 · Cited by 190
Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
Kumra, S., Oberstar, J. V., Sikich, L., Findling, R. L., McClellan, J. M., Vinogradov, S., & Schulz, S. C. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm109 · Cited by 189
Adult Neurogenesis and Psychiatric DisordersPreprint
Kang, E., Wen, Z., Song, H., Christian, K. M., & Ming, G. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019026 · Cited by 190
Clozapine versus other atypical antipsychotics for schizophrenia
Lobos, C. A., Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006633.pub2 · Cited by 196
The pipeline and future of drug development in schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002062 · Cited by 182
Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap
Pratt, J. A., Winchester, C. L., Dawson, N., & MORRIS, B. J. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3649 · Cited by 199
Cerebral cortex : principles of operation
Rolls, E. T. (2016) · doi:10.82444/warw.33712699 · Cited by 187
Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis
Zhang, J., Lencz, T., Zhang, R. X., Nitta, M., Maayan, L. A., John, M., Robinson, D. G., Fleischhacker, W. W., Kahn, R. S., Ophoff, R. A., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw058 · Cited by 186
Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
Grajales, D., Ferreira, V., & Valverde, Á. M. (2019) · Cells · doi:10.3390/cells8111336 · Cited by 194
Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia
Nord, M., & Farde, L. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00222.x · Cited by 178
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action
Dedic, N., JONES, P. G., Hopkins, S. C., Lew, R., Shao, L., Campbell, J. E., Spear, K. L., Large, T. H., Campbell, U. C., Hanania, T., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.260281 · Cited by 181
A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia
Lieberman, J. A., Dunbar, G. C., Segreti, A. C., Girgis, R. R., Seoane, F., Beaver, J. S., Duan, N., & Hosford, D. A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.259 · Cited by 176
Self-citation
Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function inNRG1+/−Knock-Outs Compared with Wild-Type Mice
Bjarnadóttir, M., Misner, D., Haverfield-Gross, S., Bruun, S., Helgason, V. G., Stefánsson, H., Sigmundsson, A., Firth, D. R., Nielsen, B., Stefansdottir, R., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4314-06.2007 · Cited by 176
Linking ADHD to the Neural Circuitry of Attention
Mueller, A., Hong, D. S., Shepard, S., & Moore, T. (2017) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2017.03.009 · Cited by 158
Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress‐induced decrease in cell proliferation and BDNF expression in rat hippocampus
Xu, H., Chen, Z., He, J., Haimanot, S., Li, X., Dyck, L. E., & Li, X. (2006) · Hippocampus · doi:10.1002/hipo.20184 · Cited by 175
Clozapine as a Model for Antipsychotic Development
Nucifora, F. C., Mihaljevic, M. M., Lee, B. J., & Sawa, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0552-9 · Cited by 182
The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review
Maletic, V., Eramo, A., Gwin, K., Offord, S. J., & Duffy, R. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00042 · Cited by 184
Psychedelics and schizophrenia
González‐Maeso, J., & Sealfon, S. C. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.005 · Cited by 178
Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors
Guo, D. M., Hillger, J. M., IJzerman, A. P., & Heitman, L. H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21307 · Cited by 167
A Dynamical Systems Hypothesis of Schizophrenia
Loh, M., Rolls, E. T., & Deco, G. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030228 · Cited by 164
Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis
Kusumi, I., Boku, S., & Takahashi, Y. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12242 · Cited by 169
Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis
Zhang, J., Robinson, D. G., Yu, J., Gallego, J. A., Fleischhacker, W. W., Kahn, R. S., Crespo‐Facorro, B., Vázquez-Bourgón, J., Kane, J. M., Malhotra, A. K., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17121363 · Cited by 164
Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity
Kanes, S., Tokarczyk, J., Siegel, S. J., Bilker, W. B., Abel, T. G., & Kelly, M. P. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.09.026 · Cited by 159
Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial
Swartz, M. S., Stroup, T. S., McEvoy, J. P., Thomas, S., Rosenheck, R. A., Keefe, R. S. E., Hsiao, J., & Lieberman, J. A. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.5.500 · Cited by 171
Self-citation
Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study
Yu, H., Yan, H., Wang, L., Li, J., Tan, L., Deng, W., Chen, Q., Yang, G., Zhang, F., Lu, T., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30049-x · Cited by 155
Adverse Effects of Risperidone on Spatial Working Memory in First-Episode Schizophrenia
Reilly, J. L., Harris, M. S. H., Keshavan, M. S., & Sweeney, J. A. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1189 · Cited by 155
Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics
Lai, C.-Y., Scarr, E., Udawela, M., Everall, I., Chen, W. J., & Dean, B. (2016) · World Journal of Psychiatry · doi:10.5498/wjp.v6.i1.102 · Cited by 153
Clinical Assessment and Management of Delirium in the Palliative Care Setting
Bush, S. H., Tierney, S., & Lawlor, P. G. (2017) · Drugs · doi:10.1007/s40265-017-0804-3 · Cited by 161
Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?
Fernø, J., Raeder, M. B., Vik‐Mo, A. O., Skrede, S., Glambek, M., Tronstad, K. J., Breilid, H., Løvlie, R., Berge, R. K., Stansberg, C. T., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500323 · Cited by 152
Randomized Multicenter Investigation of Folate Plus Vitamin B 12 Supplementation in Schizophrenia
Roffman, J. L., Lamberti, J. S., Achtyes, E. D., Macklin, E. A., Galendez, G. C., Raeke, L. H., Silverstein, N. J., Smoller, J. W., Hill, M. B., & GOFF, D. C. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.900 · Cited by 150
Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia
Arnsten, A. F. T., Girgis, R. R., Gray, D. L., & Mailman, R. B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.028 · Cited by 152
Dopamine D1receptor ligands: Where are we now and where are we going
Zhang, J., Xiong, B., Zhen, X., & Zhang, A. (2008) · Medicinal Research Reviews · doi:10.1002/med.20130 · Cited by 146
The Cytokine Model of Schizophrenia: Emerging Therapeutic Strategies
Girgis, R. R., Kumar, S. S., & Brown, A. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.002 · Cited by 138
G protein-coupled receptors in major psychiatric disorders
Catapano, L. A., & Manji, H. K. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.09.025 · Cited by 133
In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders
Nikolaus, S., Antke, C., & Müller, H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.009 · Cited by 128
Inhibitory effects of aripiprazole on interferon‐γ‐induced microglial activation via intracellular Ca2+ regulation in vitro
Kato, T. A., Mizoguchi, Y., Monji, A., Horikawa, H., Suzuki, S. O., Seki, Y., Iwaki, T., Hashioka, S., & Kanba, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05435.x · Cited by 123
Schizophrenia: New Pathological Insights and Therapies
Jarskog, L. F., Miyamoto, S., & Lieberman, J. A. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.060904.084114 · Cited by 119
Self-citation
Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target
Wiklund, E. D., Catts, V. S., Catts, S. V., Ng, T. F., Whitaker, N. J., Brown, A. J., & Lutze-Mann, L. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24813 · Cited by 119
Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment
Weiner, I., & Arad, M. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.004 · Cited by 119
Development of risperidone liposomes for brain targeting through intranasal route
Narayan, R., Singh, M., Ranjan, O. P., Nayak, Y., Garg, S., Shavi, G. V., & Nayak, U. Y. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.08.033 · Cited by 118
Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia
Lodge, D. J., & Grace, A. A. (2008) · Neurotoxicity Research · doi:10.1007/bf03033801 · Cited by 119
The Dopamine D2 Receptor: New Surprises from an Old Friend
Bonci, A., & Hopf, F. W. (2005) · Neuron · doi:10.1016/j.neuron.2005.07.015 · Cited by 115
Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia
Meyer, U., Spoerri, E., Yee, B. K., Schwarz, M., & Feldon, J. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn131 · Cited by 117
Antidepressants- and antipsychotics-induced hepatotoxicity
Todorović, N., Đorđević, J., Pejić, S., Đorđević, N. O., & Pajović, S. B. (2021) · Archives of Toxicology · doi:10.1007/s00204-020-02963-4 · Cited by 121
Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment
Urigüen, L., García-Fuster, M. J., Callado, L. F., Morentín, B., Harpe, R. L., Casadó, V., Lluís, C., Franco, R., Garcı́a-Sevilla, J. A., & Meana, J. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1608-2 · Cited by 115
Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function
Ogino, S., Miyamoto, S., Miyake, N., & Yamaguchi, N. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12088 · Cited by 113
Self-citation
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study
Kerwin, R. W., Millet, B., Herman, E., Bánki, C. M., Lublin, H., Pans, M., Hanssens, L., L'Italien, G. J., McQuade, R. D., & Beuzen, J. N. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.03.002 · Cited by 113
Variants of Dopamine and Serotonin Candidate Genes as Predictors of Response to Risperidone Treatment in First-Episode Schizophrenia
Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kitajima, T., Yoshimura, R., Hashimoto, S., O’Donovan, M. C., Nakamura, J., Ozaki, N., & Iwata, N. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1437 · Cited by 111
Theranostic Biomarkers for Schizophrenia
Perković, M. N., Erjavec, G. N., Štrac, D. Š., Uzun, S., Kozumplik, O., & Pivac, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040733 · Cited by 113
Disrupted sleep and circadian rhythms in schizophrenia and their interaction with dopamine signaling
Ashton, A., & Jagannath, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00636 · Cited by 106
Acute administration of typical and atypical antipsychotics reduces EEG gamma power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in gamma power
Jones, N. C., Reddy, M., Anderson, P., Salzberg, M. R., O'Brien, T. J., & Pinault, D. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000848 · Cited by 105
A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory
Smith, J. W., Gastambide, F., Gilmour, G., Dix, S. L., Foss, J., Lloyd, K. G., Malik, N. K., & Tricklebank, M. D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2277-5 · Cited by 109
Therapeutic Drug Monitoring of Common Antipsychotics
Patteet, L., Morrens, M., Maudens, K. E. K., Niemegeers, P., Sabbe, B., & Neels, H. M. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3182708ec5 · Cited by 107
Atypical Antipsychotics Alter Cholesterol and Fatty Acid Metabolism in Vitro
Canfrán-Duque, A., Casado, M. E., Pastor, Ó., Sánchez-Wandelmer, J., de la Peña, G., Lerma, M., Mariscal, P., Bracher, F., Lasunción, M. A., & Busto, R. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m026948 · Cited by 105
Effects of antipsychotic medications on sleep in schizophrenia
Krystal, A. D., Goforth, H. W., & Roth, T. G. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f39703 · Cited by 105
A Prospective Cohort Study of Antipsychotic Medications in Pregnancy: The First 147 Pregnancies and 100 One Year Old Babies
Kulkarni, J., Worsley, R., Gilbert, H., Gavrilidis, E., Rheenen, T. E. V., Wang, W., McCauley, K., & Fitzgerald, P. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094788 · Cited by 104
Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver
Fernø, J., Vik‐Mo, A. O., Jassim, G., Håvik, B., Berge, K., Skrede, S., Gudbrandsen, O. A., Waage, J. E. R., Lunder, N., Mørk, S. J., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1370-x · Cited by 107
Developing treatments for impaired cognition in schizophrenia
Minzenberg, M., & Carter, C. S. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.017 · Cited by 106
Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway
Girgis, R. R., Javitch, J. A., & Lieberman, J. A. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.40 · Cited by 102
Self-citation
Positive Allosteric Modulation of Metabotropic Glutamate 5 (mGlu5) Receptors Reverses N-Methyl-D-Aspartate Antagonist-Induced Alteration of Neuronal Firing in Prefrontal Cortex
Lecourtier, L., Homayoun, H., Tamagnan, G. D., & Moghaddam, B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.003 · Cited by 103
Therapies for dopaminergic‐induced dyskinesias in parkinson disease
Gottwald, M. D., & Aminoff, M. J. (2011) · Annals of Neurology · doi:10.1002/ana.22423 · Cited by 101
Multi-Target Approach for Drug Discovery against Schizophrenia
Kondej, M., Stępnicki, P., & Kaczor, A. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103105 · Cited by 106
Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics
Meltzer, H. Y. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_4 · Cited by 97
Antibodies to Surface Dopamine-2 Receptor and N-Methyl-D-Aspartate Receptor in the First Episode of Acute Psychosis in Children
Pathmanandavel, K., Starling, J., Merheb, V., Ramanathan, S., Sinmaz, N., Dale, R. C., & Brilot, F. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.07.014 · Cited by 98
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme
Bugarski‐Kirola, D., Iwata, N., Sameljak, S., Reid, C., Blaettler, T., Millar, L., Marques, T. R., Garibaldi, G. M., & Kapur, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30344-3 · Cited by 102

Authors: Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A.
Affiliations: St. Marianna University School of Medicine (JP)
University of North Carolina at Chapel Hill (US)
Duke Medical Center (US)
Corresponding author: Lieberman, J A
Venue: Molecular Psychiatry
Publisher: Springer Science and Business Media LLC
Published: 2004-08-03
Volume: 10
Issue: 1
Pages: 79-104
ISSN: 1359-4184 (ISSN-L)
1476-5578
DOI: 10.1038/sj.mp.4001556
OpenAlex: W2132980997
Cited by: 988
References: 393
Citations by year: 2026: 23 · 2025: 25 · 2024: 32 · 2023: 40 · 2022: 37 · 2021: 40 · 2020: 45 · 2019: 42 · 2018: 40 · 2017: 41 · 2016: 54 · 2015: 52 · 2014: 46 · 2013: 72 · 2012: 66
FWCI: 4.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Molecular Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health (MH064065, P50MH064065)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, dopamine D2 receptor, atypical antipsychotics, partial dopamine agonist, typical antipsychotics, mechanism of action, antipsychotic adverse effects, adjunctive pharmacotherapy, antipsychotic drug development, schizophrenia pathophysiology
MeSH terms: Behavioral Symptoms, Humans, Schizophrenia, Antipsychotic Agents, Drug Design, Dopamine Agents, Receptors, Dopamine D2, Receptors, Glutamate, Excitatory Amino Acid Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks